Profile picture of Carolyn Bampton

Dr Carolyn Bampton

MBBS, FRACP
Medical Oncologist
Become a Patient

Dr Carolyn Bampton is dedicated to delivering the highest level of care to her patients, bringing a compassionate and patient-centred approach to her practice.

Biography

Dr Carolyn Bampton is an experienced medical oncologist at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. She attended the University of Adelaide where she obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS) and completed specialist oncology training at the Royal Adelaide Hospital. Dr Bampton subsequently completed palliative medicine training at Sydney’s Concord Hospital from 1997-1998 before joining Icon Cancer Centre Adelaide. She previously held the position of visiting medical oncologist at the Modbury Public Hospital for over 12 years.

Dr Bampton maintains an active interest in medical education, clinical research and clinical trials. She is a clinical advisor for the Adelaide Community Health Care Alliance hospitals Medical Advisory Committee and is a senior clinical lecturer at Adelaide University. Dr Bampton has participated as local principal investigator and co-principal investigator on several gastrointestinal cancer studies. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in clinical research, clinical trials, gastrointestinal, brain, prostate, breast and lung cancers.

Affiliations & Memberships

  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Carolyn Bampton accepts referrals for all cancer types, with a special clinical interest in:
  • Brain cancer and CNS
  • Breast cancer
  • Gastrointestinal cancer
  • Lung cancer
  • Prostate cancer

Icon Locations

Adelaide (Kurralta Park) View centre
Adelaide (Windsor Gardens) View centre

Publications

  • Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. J. Tie, J.D. Cohen, Y. Wang, L. Li, M. Christie, K. Simons, H. Elsaleh, S. Kosmider, R. Wong, D. Yip, M. Lee, B.Tran, D. Rangiah, M. Burge, D. Goldstein, M. Singh, I. Skinner, I. Faragher, M. Croxford, C. Bampton, A. Haydon, I.T. Jones, C.S. Karapetis, T. Price, M.J. Schaefer, J. Ptak, L. Dobbyn, N. Silliman, I. Kinde, C. Tomasetti, N. Papadopoulos, K. Kinzler, B. Volgestein & P. Gibbs. Gut, 2019; 68: 663-671.

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. A. Wang-Gillam, C. Li, G. Bodoky, A. Dean, Y. Shan, G. Jameson, T. Macrarulla, K. Lee, D. Cunningham, J.F. Blanc, R.A. Hubner, C. Chiu, G. Schwartsmann, J.T. Siveke, F. Braiteh, V. Moyo, B. Belanger, N. Dhindsa & M. Wing. The Lancet, 2016. 387 (10018): 545-557.

View all

Search